Up-Front Treatment of Diffuse Large-B Cell Lymphoma (DLBCL) in Elderly Patients with Rituximab in Combination with CHOP-Like Chemotherapy: A Multicenter Study on the Current Clinical Management.
Miguel Canales(Hospital Universitario La Paz), F. Hernández‐Navarro(Hospital Universitario La Paz), Rosa Ayala(Hospital Universitario 12 De Octubre), Javier de la Serna(Hospital Universitario 12 De Octubre), Mariano Provencio(Hospital Universitario Puerta de Hierro Majadahonda), Raquel Gil(Hospital Universitario La Paz), Joaquín Diaz‐Mediavilla(Hospital Clínico San Carlos), Ana Alvarez(Hospital Clínico San Carlos), Ricardo Pérez(Hospital General Universitario Gregorio Marañón), Antonio Sánchez(Institut d'Estadística de Catalunya)
Cited by 1
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907